Unique ID issued by UMIN | UMIN000017397 |
---|---|
Receipt number | R000020183 |
Scientific Title | Hepatic Resection for Colorectal Liver Metastases following Panitumumab(Vectibix) with Chemotherapy Cohort study |
Date of disclosure of the study information | 2015/05/02 |
Last modified on | 2015/12/04 17:05:52 |
Hepatic Resection for Colorectal Liver Metastases following
Panitumumab(Vectibix) with Chemotherapy Cohort study
Hepatic Resection for Colorectal Liver Metastases following
Panitumumab(Vectibix) with Chemotherapy Cohort study
Hepatic Resection for Colorectal Liver Metastases following
Panitumumab(Vectibix) with Chemotherapy Cohort study
Hepatic Resection for Colorectal Liver Metastases following
Panitumumab(Vectibix) with Chemotherapy Cohort study
Japan |
Unresectable colorectalcancer with hepatic metastases
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Malignancy
NO
The aim is to evaluate the complete hepatic resection rate of panitumumab as the first line chemotherapy for unresectable colorectal cancer with hepatic metastasis.
Efficacy
Exploratory
Others
Phase I
Complete hepatic resection rate
Hepatic resection rate, response rate, complications after hepatic resection, adverse event
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. The cases histologically diagnosed as colorectal cancer
2. The cases with evaluative resectable hepatic metastatic lesions ,synchronously or metachronously
3. Unresectable hepatic metastases mean anatomic difficulty and so on.
4. The cases with possibility of hepatic resection after panitumumab chemotherapy
5. The age is 20 years old or older.
6. Performance status is 0-2 cases
7. A major organ function is maintained by a laboratory study within 14 days before registration.
8. An agreement is obtained in a document from the patients after informed consent.
1. The cases with serious drug hyper reaction against panitumumab, fluorouracil folinic acid, oxaliplatin, irinotecan
2. The cases with serious hypersensitivity having functional disorder or sensory disturbance
3. The cases with bone marrow suppression or its history, systemic infection, interstitial pneumonia, diarrhea, ileus, a lot of ascites or hydrothorax, icterus
4. The cases with interstitial pneumonia or its history
5. The cases with serious complications
- Poor control diabetes mellitus
- Heart failure beyond NYHA3
- Renal failure
- Liver failure
6. The cases with mutative or unjudged type about KRAS status
7. The cases without a history of chemotherapy
8. Pregnant or lactating women
9. The cases judged to be unsuitable for registration
100
1st name | |
Middle name | |
Last name | Akinobu Taketomi |
Hokkaido University Graduate school of medicine
Gastroenterological Surgery1
North15 West7, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5927
taketomi@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Norihiko Takahashi |
Hokkaido University Hospital
Gastroenterology1
North15 West7, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5927
noripiko@med.hokudai.ac.jp
Gastroenterological Surgery1, Hokkaido University Graduate school of medicine
Hokkaido University Hospital
Other
NO
2015 | Year | 05 | Month | 02 | Day |
Unpublished
Terminated
2012 | Year | 06 | Month | 13 | Day |
2012 | Year | 08 | Month | 22 | Day |
Observation of complete hepatic resection rate
2015 | Year | 05 | Month | 02 | Day |
2015 | Year | 12 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020183